The latest buzz around the popular weight loss drugs Ozempic, Mounjaro and Wegovy is to reduce the doseage and therefore avoid the vomiting and headaches that can happen on normal doses. But it’s not ...

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

News Do Certain Diabetes Drugs Increase the Risk of Acute Kidney Injury in Patients Taking Anti-Cancer Therapies? Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medicatio ...

The Impact of New Weight Loss Drugs on Dietetics By Carrie Dennett, MPH, RDN Today’s Dietitian Vol. 26 No. 9 P. 14 What’s changed for weight-inclusive and weight management dietitians?

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

Nearly 16% of American adults -- that's close to 1 in 6 -- now has diabetes, according to the latest data from the U.S.

In a Q&A, an FDA spokesperson discusses efforts to reduce misinformation about biosimilars through education, the agency’s ...

Among privately insured patients, there was a doubling in the use of GLP-1 RAs as antiobesity treatment from 2022 to 2023, with a simultaneous 25.6% decrease in the rate of metabolic bariatric surgery ...

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...